Guanabenz ( DrugBank: Guanabenz )


2 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1
13Multiple sclerosis/Neuromyelitis optica1

2. Amyotrophic lateral sclerosis


Clinical trials : 645 Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-005367-32-IT
(EUCTR)
29/02/201617/03/2017Clinical study on the efficacy and tolerabilty of Guabenz in Amiotropic Lateral SclerosisPROTEIN MISFOLDING, AMYOTROPHIC LATERAL SCLEROSIS AND GUANABENZ: A PHASE II RCT WITH FUTILITY DESIGN - PROMISE Amiotrophic Lateral Sclerosis
MedDRA version: 19.1;Level: PT;Classification code 10028003;Term: Motor neurone disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: GUANABENZ ACETATO
Product Code: GUANA2015
INN or Proposed INN: GUANABENZ
Other descriptive name: GUANABENZ
Product Name: RILUZOLO
INN or Proposed INN: RILUZOLO
Other descriptive name: RILUZOLO
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
208Phase 2Italy

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02423083
(ClinicalTrials.gov)
April 21, 201521/4/2015Oral Guanabenz for Multiple SclerosisPhase I Study of Oral Guanabenz for Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting;Multiple SclerosisDrug: GuanabenzNational Institute of Neurological Disorders and Stroke (NINDS)NULLTerminated18 Years55 YearsAll2Phase 1United States